-transparent.png){kind=logo}
Polymorphonuclear leucocytes (PMN) from patients with systemic lupus erythematosus (SLE) were isolated from defibrinated and heparinized blood. In addition, PMN from a healthy donor were incubated with sera from SLE patients and with sera containing artificially prepared immune complexes of hepatitis B surface antigen (HBsAg) and human anti-HBsAg immunoglobulin (anti-HBs) with well defined variations of the antigen/antibody ratio. To one group of blood samples, 5 mM monoiodine acetic acid (MIAA) was added to block in vitro phagocytosis. The Pmn were examined for the presence of IgG, IgM, and HBsAg by the immunofluorescence technique. PMN from defibrinated blood of SLE patients showed in up to 80% immunoglobulin (Ig)-inclusions. However, addition of 5 mM MIAA reduced the number of Ig-containing PMN to at most 40%, which levels were equal to numbers found in specimens from heparinized blood. Addition of 5 mM MIAA to heparinized blood did not reduce the number of PMN with Ig inclusions. Normal donor PMN isolated from defibrinated, heparinized, and EDT blood showed equal amounts of Ig inclusions after incubation with SLE sera, but none when MIAA had been added. In PMN incubated with HBsAg-anti HBs immune complexes with an antigen antibody ratio between 5 and 0-2, both HBsAg and IgG could be detected. It is concluded that Ig inclusions in PMN from heparinized blood from SLE patients are due to in vivo phagocytosis, presumably of circulating immune complexes. In vitro phagocytosis of Ig from SLE sera by normal donor PMN also suggests the presence of immune complexes. Dependent on the antigen-antibody ratio, artificial HBsAg/anti-HBs immune complexes can be detected by in vitro phagocytosis by PM.
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
December 1969,
The Japanese journal of experimental medicine,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
October 1979,
Ryumachi. [Rheumatism],
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
June 1986,
Clinical and experimental immunology,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
July 1982,
Clinical immunology and immunopathology,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
June 1982,
Immunology,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
February 1986,
Immunopharmacology,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
March 1985,
Biochemical and biophysical research communications,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
January 1978,
Acta physiologica Academiae Scientiarum Hungaricae,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
June 1977,
Clinical and experimental immunology,
J W Steffelaar, and
F J Ten Kate, and
M Nap, and
A J Swaak, and
C B De Graaffreitsma, and
E H Van Elven, and
T M Feltkamp-Vroom
February 1979,
Annals of the rheumatic diseases,
